About Achillion Pharmaceuticals
Achillion Pharmaceuticals, Inc. is a biopharmaceutical company. The Company's primary business is to discover, develop and commercialize small molecule therapeutics for the treatment of infectious diseases and immune system disorders. The Company is focused on its complement inhibitor platform, directed at advancing small molecule compounds that have the potential to be used in the treatment of immune-related diseases associated with the complement system. The complement system is part of the body's immune system. The Company has initiated a first-in-human Phase I clinical trial for its first complement factor D inhibitor, ACH-4471, to assess safety, tolerability, pharmacokinetics, or PK, and pharmacodynamics, or PD. The Company has developed a portfolio of drug candidates, including odalasvir, ACH-3422 and sovaprevir.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Biotechnology
- Sub-Industry: Biotechnology
- Exchange: NASDAQ
- Symbol: ACHN
- CUSIP: 00448Q20
- Previous Close: $4.35
- 50 Day Moving Average: $4.26
- 200 Day Moving Average: $5.93
- 52-Week Range: $3.78 - $10.06
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -10.50
- P/E Growth: -0.42
- Market Cap: $574.06M
- Outstanding Shares: 136,680,000
- Beta: 1.59
- Return on Equity: -9.46%
- Return on Assets: -9.16%
Companies Related to Achillion Pharmaceuticals:
- Current Ratio: 29.93%
- Quick Ratio: 29.93%
What is Achillion Pharmaceuticals' stock symbol?
Achillion Pharmaceuticals trades on the NASDAQ under the ticker symbol "ACHN."
Where is Achillion Pharmaceuticals' stock going? Where will Achillion Pharmaceuticals' stock price be in 2017?
9 analysts have issued 12 month price objectives for Achillion Pharmaceuticals' stock. Their forecasts range from $5.00 to $16.00. On average, they anticipate Achillion Pharmaceuticals' stock price to reach $10.50 in the next twelve months.
When will Achillion Pharmaceuticals announce their earnings?
Achillion Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Thursday, February, 23rd 2017.
Who owns Achillion Pharmaceuticals stock?
Achillion Pharmaceuticals' stock is owned by a variety of of retail and institutional investors. Top institutional investors include Orbimed Advisors LLC (9.59%), State Street Corp (3.75%), Janus Capital Management LLC (3.41%), Numeric Investors LLC (1.99%), FMR LLC (1.11%) and Renaissance Technologies LLC (0.69%). Company insiders that own Achillion Pharmaceuticals stock include David Apelian, Jason S Fisherman, Joel C Barrish, Mary Kay Fenton and Nicole Vitullo.
Who sold Achillion Pharmaceuticals stock? Who is selling Achillion Pharmaceuticals stock?
Achillion Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including RTW Investments LP, FMR LLC, Janus Capital Management LLC, Turner Investments LLC, Oxford Asset Management and Metropolitan Life Insurance Co. NY.
Who bought Achillion Pharmaceuticals stock? Who is buying Achillion Pharmaceuticals stock?
Achillion Pharmaceuticals' stock was bought by a variety of institutional investors in the last quarter, including Numeric Investors LLC, State Street Corp, Renaissance Technologies LLC, Bogle Investment Management L P DE, Dimensional Fund Advisors LP, Two Sigma Investments LP, GSA Capital Partners LLP and Tudor Investment Corp Et Al. Company insiders that have bought Achillion Pharmaceuticals stock in the last two years include Jason S Fisherman, Joel C Barrish and Mary Kay Fenton.
How do I buy Achillion Pharmaceuticals stock?
Shares of Achillion Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How much does a share of Achillion Pharmaceuticals stock cost?
One share of Achillion Pharmaceuticals stock can currently be purchased for approximately $4.20.